TECHNOLOGY LICENSING OPPORTUNITY: Clathrate Therapeutics Platform

The Clathrate Therapeutics Platform is a novel technology that enables controlled, localized delivery of therapeutic gases at the site of disease. This platform has the potential to unlock new commercial opportunities in areas where gas-based therapeutics have shown promise but faced delivery limitations. The technology uses a proprietary, controlled-release system designed to localize therapeutic gases at the intended treatment site, minimizing systemic exposure. The key advantages of this platform include localized delivery, controlled release, improved safety margin, platform versatility, development optimization, and partnership-ready architecture. The market applications for this technology include oncology therapeutics, cardiovascular and vascular medicine, neurology and neurodegenerative disease, regenerative medicine, and medical device and drug-device combination companies. • Localized delivery: Targets therapeutic gases to the intended site while minimizing systemic exposure. • Controlled release: Designed for sustained, tunable dosing under physiological conditions. • Improved safety margin: Aims to separate therapeutic effect from toxicity risk. • Platform versatility: Applicable across oncology, cardiovascular, neurological, and regenerative indications. • Development optimization: Supported by predictive modeling to guide dose and design decisions. • Partnership-ready architecture: Suitable for integration with drug-device combinations and existing treatment modalities.